Innocan Pharma Secures Patent for LPT-CBD Technology in Japan's $102 Billion Pharmaceutical Market
Key Insights
Innocan Pharma (search) received patent allowance for its Liposomal CBD Injection Technology (LPT-CBD) in Japan, the world's third-largest pharmaceutical market valued at approximately $102 billion.
The patent protects a prolonged-release liposome-based formulation that encapsulates synthetic CBD, demonstrating pain-relief effects lasting up to four weeks in preclinical studies.
This marks Innocan's second patent grant for LPT-CBD following approval in India, strengthening the company's global intellectual property portfolio for non-opioid chronic pain management.
Innocan Pharma (search) Corporation has secured patent allowance for its Liposomal CBD Injection Technology (LPT-CBD) in Japan, marking a significant milestone in the world's third-largest pharmaceutical market valued at approximately $102 billion. The patent covers a prolonged-release liposome-based formulation that encapsulates cannabinoids, positioning the company to advance its non-opioid chronic pain management solution in a major global market.
Patent Protection Strengthens Global IP Portfolio
The newly allowed patent protects Innocan's LPT-CBD formulation designed for sustained release of synthetic CBD into the bloodstream. This achievement represents the company's second patent grant for LPT-CBD, following approval in India, and forms part of a broad international patent family currently under examination in multiple jurisdictions worldwide.
"We are thrilled to receive this patent allowance for our proprietary technology," said Iris Bincovich, Chief Executive Officer of Innocan Pharma (search). "This allowance marks our second patent to be granted for LPT-CBD, following the one granted in India, further strengthening our innovation and global IP position. We look forward to a series of additional patent approvals worldwide."
Innovative Drug Delivery Platform Shows Promise
Developed in collaboration with Professor Chezy Barenholz and Dr. Ahuva Cern from the Hebrew University (search) in Jerusalem, the liposomal drug delivery platform allows for prolonged exposure and maximizes the bioavailability and therapeutic effects of CBD. LPT-CBD has demonstrated prolonged pharmacokinetics and pain-relief effects lasting up to four weeks, supported by multiple preclinical studies.
Professor Chezy Barenholz, Head of the company's Advisory Board, stated, "The allowance of this patent provides strong evidence to the dedication and expertise of our development teams in driving innovation. LPT-CBD is the first drug product in our pipeline that we are currently advancing under this intellectual property portfolio."
FDA Provides Positive Development Feedback
Following a successful pre-IND meeting, the U.S. Food and Drug Administration (FDA) provided positive feedback to advance the development of LPT-CBD as a non-opioid alternative for chronic pain management. This regulatory milestone supports the company's progression toward FDA approval.
Dr. Eyal Kalo, Vice President of R&D, added, "LPT-CBD is progressing under a streamlined development plan toward FDA approval. We are extremely proud of this patent allowance and remain dedicated to advancing LPT-CBD as a non-opioid alternative for chronic pain management."
Strategic Market Position
The patent allowance in Japan represents an important milestone for Innocan in advancing LPT-CBD as a leading non-opioid solution for chronic pain management. The company operates as an innovator in the pharmaceuticals and wellness sectors, focusing on developing a CBD-loaded liposome drug delivery platform with exact dosing and prolonged, controlled release of synthetic CBD for non-opioid pain management.